| abstract |
Compound represented by the structural formula n n n or a pharmaceutically acceptable salt thereof, wherein n Ar 1 and Ar 2 are optionally substituted heteroaryl or optionally substituted phenyl; n X 1 is —O—, —S—, —SO—, —SO 2 —, —NR 12 —, —NCOR 12 — or —NR 12 SO 2 R 15 ; n n n is selected from the group consisting of n n n X 2 is —O—, —S— or —NR 5 ; n Y is ═O, ═S or ═NR 11 ; n Y 1 is H, C 1 -C 6 alkyd, —NR 17 R 15 , —SCH 3 , R 19 -aryl(CH 2 ) n6 —, R 19 -heteroaryl-(CH 2 ) n6 —, —(CH 2 ) n6 -heterocycloalkyl, -(C 1 -C 3 )alkyl-NH—C(O)O(C 1 -C 6 )alkyl or —NHC(O)R 15 ; n R 5 is H or —(CH 2 ) n1 -G, wherein n 1 is 0-5, G is H, —CF 3 , —CHF 2 , —CH 2 F, —OH, —O— (C 1 -C 6 alkyl), —SO 2 R 13 , —O—(C 3 -C 8 cycloalkyl), —NR 13 R 14 , —SO 2 NR 13 R 14 , —NR 13 SO 2 R 15 , —NR 13 COR 12 , —NR 12 (CONR 13 R 14 ), —CONR 13 R 14 , —COOR 12 , C 3 -C 8 cycloalkyl, R 19 -aryl, R 19 -heteroaryl, and provided when n 1 =0, G is not H; n R 1 , R 2 , R 3 and R 7 are H, alkyl, cycloalkyl, —CHF 2 , —CH 2 F or —CF 3 ; or R 1 and R 2 , together with the carbon to which they are attached, form an alkylene ring; or R 1 and R 2 together are ═O, n R 6 is R 7 or —OH; n and the remaining variables are as defined in the specifiation, methods of treating diseases susceptible to treatment with neurokinin antagonists with said compounds, and pharmaceutical compositions comprising said compounds are disclosed. n Also disclosed are pharmaceutical compositions comprising an effective amount of a compound of claim 1, at least one pharmaceutically acceptable carrier, and in combination with an effective amount of a selective serotonin reuptake inhibitor. |